Autopsy report · NCT01254656
A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022
Cause of deathNo reason given
“See termination reason in detailed description.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 2 months before it stopped.
- 108 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- HIV-1
- Interventions
- lersivirine; lersivirine; efavirenz; lersivirine; lersivirine; etravirine
- Participants
- 108
- Sites
- 23
- Countries
- Australia, Brazil, Canada, Italy, Mexico, Poland, South Africa, Switzerland, United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.